BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 11322786)

  • 1. Cross-talk between signal transducer and activator of transcription 3 and androgen receptor signaling in prostate carcinoma cells.
    Matsuda T; Junicho A; Yamamoto T; Kishi H; Korkmaz K; Saatcioglu F; Fuse H; Muraguchi A
    Biochem Biophys Res Commun; 2001 Apr; 283(1):179-87. PubMed ID: 11322786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protein inhibitor of activated STAT3 regulates androgen receptor signaling in prostate carcinoma cells.
    Junicho A; Matsuda T; Yamamoto T; Kishi H; Korkmaz K; Saatcioglu F; Fuse H; Muraguchi A
    Biochem Biophys Res Commun; 2000 Nov; 278(1):9-13. PubMed ID: 11071847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
    Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M
    Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TGF-beta signaling and androgen receptor status determine apoptotic cross-talk in human prostate cancer cells.
    Zhu ML; Partin JV; Bruckheimer EM; Strup SE; Kyprianou N
    Prostate; 2008 Feb; 68(3):287-95. PubMed ID: 18163430
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor.
    Hobisch A; Eder IE; Putz T; Horninger W; Bartsch G; Klocker H; Culig Z
    Cancer Res; 1998 Oct; 58(20):4640-5. PubMed ID: 9788616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interleukin 6 activates androgen receptor-mediated gene expression through a signal transducer and activator of transcription 3-dependent pathway in LNCaP prostate cancer cells.
    Chen T; Wang LH; Farrar WL
    Cancer Res; 2000 Apr; 60(8):2132-5. PubMed ID: 10786674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Constitutive activation of nuclear factor kappaB p50/p65 and Fra-1 and JunD is essential for deregulated interleukin 6 expression in prostate cancer.
    Zerbini LF; Wang Y; Cho JY; Libermann TA
    Cancer Res; 2003 May; 63(9):2206-15. PubMed ID: 12727841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic activation of the androgen receptor by bombesin and low-dose androgen.
    Dai J; Shen R; Sumitomo M; Stahl R; Navarro D; Gershengorn MC; Nanus DM
    Clin Cancer Res; 2002 Jul; 8(7):2399-405. PubMed ID: 12114445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dihydrotestosterone interacts with EGFR/MAPK signalling and modulates EGFR levels in androgen receptor-positive LNCaP prostate cancer cells.
    Mukherjee B; Mayer D
    Int J Oncol; 2008 Sep; 33(3):623-9. PubMed ID: 18695894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional localization and competition between the androgen receptor and T-cell factor for nuclear beta-catenin: a means for inhibition of the Tcf signaling axis.
    Mulholland DJ; Read JT; Rennie PS; Cox ME; Nelson CC
    Oncogene; 2003 Aug; 22(36):5602-13. PubMed ID: 12944908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of p300 histone acetyltransferase activity and acetylation of the androgen receptor by bombesin in prostate cancer cells.
    Gong J; Zhu J; Goodman OB; Pestell RG; Schlegel PN; Nanus DM; Shen R
    Oncogene; 2006 Mar; 25(14):2011-21. PubMed ID: 16434977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An androgen-IL-6-Stat3 autocrine loop re-routes EGF signal in prostate cancer cells.
    Aaronson DS; Muller M; Neves SR; Chung WC; Jayaram G; Iyengar R; Ram PT
    Mol Cell Endocrinol; 2007 May; 270(1-2):50-6. PubMed ID: 17374439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survivin mediates resistance to antiandrogen therapy in prostate cancer.
    Zhang M; Latham DE; Delaney MA; Chakravarti A
    Oncogene; 2005 Apr; 24(15):2474-82. PubMed ID: 15735703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin-8 signaling promotes androgen-independent proliferation of prostate cancer cells via induction of androgen receptor expression and activation.
    Seaton A; Scullin P; Maxwell PJ; Wilson C; Pettigrew J; Gallagher R; O'Sullivan JM; Johnston PG; Waugh DJ
    Carcinogenesis; 2008 Jun; 29(6):1148-56. PubMed ID: 18487223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells.
    Murthy S; Agoulnik IU; Weigel NL
    Prostate; 2005 Sep; 64(4):362-72. PubMed ID: 15754350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Androgen receptor activity at the prostate specific antigen locus: steroidal and non-steroidal mechanisms.
    Jia L; Kim J; Shen H; Clark PE; Tilley WD; Coetzee GA
    Mol Cancer Res; 2003 Mar; 1(5):385-92. PubMed ID: 12651911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin-6 protects LNCaP cells from apoptosis induced by androgen deprivation through the Stat3 pathway.
    Lee SO; Lou W; Johnson CS; Trump DL; Gao AC
    Prostate; 2004 Aug; 60(3):178-86. PubMed ID: 15176047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A cross-talk between the androgen receptor and the epidermal growth factor receptor leads to p38MAPK-dependent activation of mTOR and cyclinD1 expression in prostate and lung cancer cells.
    Recchia AG; Musti AM; Lanzino M; Panno ML; Turano E; Zumpano R; Belfiore A; Andò S; Maggiolini M
    Int J Biochem Cell Biol; 2009 Mar; 41(3):603-14. PubMed ID: 18692155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interruption of nuclear factor kappaB signaling by the androgen receptor facilitates 12-O-tetradecanoylphorbolacetate-induced apoptosis in androgen-sensitive prostate cancer LNCaP cells.
    Altuwaijri S; Lin HK; Chuang KH; Lin WJ; Yeh S; Hanchett LA; Rahman MM; Kang HY; Tsai MY; Zhang Y; Yang L; Chang C
    Cancer Res; 2003 Nov; 63(21):7106-12. PubMed ID: 14612503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. C/EBPdelta is a downstream mediator of IL-6 induced growth inhibition of prostate cancer cells.
    Sanford DC; DeWille JW
    Prostate; 2005 May; 63(2):143-54. PubMed ID: 15486993
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.